cash flow reconciliationreview2024-06-30
Operating, investing and financing flows differ from the reported change in cash by 2176000, beyond tolerance 1000000.
Revenue
$0
Fiscal year ended 2024-09-30Operating income
-$5.06M
Fiscal year ended 2024-09-30Free cash flow
Unavailable
Fiscal year ended 2024-09-30PALVELLA THERAPEUTICS, INC. (PVLA) reported revenue of $0 and net income of -$6.78M for the fiscal year ended 2024-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PALVELLA THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $53.00K | $1.05M | $19.52M | $20.06M | $1.94M | $5.85M | $5.37M | $3.70M |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$5.06M | -$2.91M | -$1.76M | $13.39M | -$11.81M | $2.06M | -$15.51M | -$11.52M | -$12.17M | -$12.33M |
| Net income | -$6.78M | -$4.17M | -$2.54M | $38.65M | -$10.75M | $3.98M | -$13.18M | -$8.10M | -$9.74M | -$10.34M |
| Research & development | $3.18M | $1.44M | $984.00K | -$28.55M | $9.60M | $14.33M | $13.42M | $13.38M | $13.59M | $11.95M |
| Weighted-average diluted shares | shares 1.77M | shares 1.77M | shares 1.77M | Unavailable | shares 1.24M | shares 1.10M | Unavailable | Unavailable | Unavailable | shares 74.12M |
| Pretax income | -$6.78M | -$4.17M | -$2.54M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | $0 | $0 | $0 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-3.94 | $-2.47 | $-1.54 | Unavailable | $-8.70 | $3.62 | Unavailable | Unavailable | Unavailable | $-0.14 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $1.88M | $1.47M | $775.00K | -$11.45M | $6.84M | $3.66M | $4.02M | $3.98M | $3.95M | $4.08M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19.36M | $19.73M | $19.08M | $7.35M | $32.89M | $44.94M | $39.74M | $38.64M | $48.42M | $54.26M |
| Total assets | $20.52M | $25.05M | $29.50M | $7.55M | $59.38M | $87.54M | $82.26M | $95.49M | $99.16M | $114.31M |
| Current assets | Unavailable | Unavailable | Unavailable | $7.55M | $59.09M | $66.47M | $60.50M | $73.42M | $78.56M | $90.90M |
| Total liabilities | Unavailable | Unavailable | Unavailable | $11.43M | $28.87M | $47.05M | $66.80M | $67.56M | $63.40M | $69.94M |
| Current liabilities | $4.25M | $6.35M | $7.53M | $2.36M | $28.87M | $34.37M | $42.88M | $36.58M | $33.52M | $35.55M |
| Total equity incl. NCI | -$87.40M | -$80.83M | -$76.87M | -$74.48M | $30.51M | $40.50M | $15.46M | -$93.78M | $35.77M | $44.36M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | $70.60M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $373.00K | $1.48M | $1.84M | $0 | $1.04M | $952.00K | $1.06M | $5.81M | $829.00K | $1.26M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $801.00K | $969.00K | $1.52M | $936.00K | $2.82M | $7.60M | $5.83M | $4.15M | $3.64M | $1.90M |
Cash flow
| Metric | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.74M | -$1.60M | -$1.10M | $20.45M | -$9.72M | -$13.43M | -$11.00M | -$12.93M | -$8.78M | -$15.58M |
| Capital expenditures | $0 | $0 | $0 | -$13.00K | $69.00K | $67.00K | $48.00K | -$11.00K | $34.00K | $629.00K |
| Investing cash flow | $142.00K | $2.18M | $9.00M | $3.45M | -$1.98M | -$1.37M | $11.90M | $1.11M | $5.47M | -$10.86M |
| Financing cash flow | $2.41M | $9.89M | $0 | -$14.78M | $0 | $19.78M | $0 | $93.00K | $282.00K | $281.00K |
| Net change in cash | -$330.00K | $8.29M | -$1.10M | -$2.96M | -$12.04M | $5.20M | $1.11M | -$9.79M | -$5.83M | -$29.48M |
| Stock-based compensation | $199.00K | $217.00K | $146.00K | -$2.30M | $966.00K | $1.05M | $884.00K | $949.00K | $974.00K | $1.30M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $0 | $0 | -$30.00K | -$198.00K | $739.00K | $758.00K | $605.00K | $575.00K | $767.00K | $583.00K |
Derived
| Metric | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | -$9.79M | -$13.50M | -$11.04M | Unavailable | -$8.81M | -$16.21M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | -60.5% | 10.3% | -801.2% | -197.0% | -226.6% | -333.4% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | -50.2% | -67.3% | -570.5% | Unavailable | -164.1% | -438.3% |
| SBC / revenue | Unavailable | Unavailable | Unavailable | Unavailable | 4.9% | 5.2% | 45.7% | 16.2% | 18.1% | 35.2% |
| Current ratio | Unavailable | Unavailable | Unavailable | 3.20x | 2.05x | 1.93x | 1.41x | 2.01x | 2.34x | 2.56x |
| Revenue YoY growth | -100.0% | -100.0% | -97.3% | -82.1% | 263.5% | 442.3% | -82.4% | -30.8% | 32.4% | 12.6% |
| Net margin | Unavailable | Unavailable | Unavailable | Unavailable | -55.1% | 19.8% | -680.9% | -138.6% | -181.3% | -279.6% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 71.4% | 693.4% | 228.9% | 253.1% | 323.1% |
| CapEx / revenue | Unavailable | Unavailable | 0.0% | -1.2% | 0.4% | 0.3% | 2.5% | -0.2% | 0.6% | 17.0% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PVLA in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
Reconciliation checks needing review
4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2024-03-31
Operating, investing and financing flows differ from the reported change in cash by 9000000, beyond tolerance 1000000.
cash flow reconciliationreview2023-12-31
Operating, investing and financing flows differ from the reported change in cash by 12002000, beyond tolerance 1000000.
balance equationreview2022-12-31
Difference 121706000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.